Polymer coatings and delayed arterial healing following drug-eluting stent implantation
- PMID: 19838148
Polymer coatings and delayed arterial healing following drug-eluting stent implantation
Abstract
The antirestenotic efficacy of drug-eluting stent (DES) technology is based on the local delivery and modulated release of cytotoxic drugs targeted at inhibition of neointimal hyperplasia. Control of drug-release kinetics is a critical component of device efficacy. To date this has been most effectively performed by stent coatings comprised of non-erodable (permanent) polymer which facilitate drug loading and delay elution of the active drug. In fact all 4 of the systems currently approved by the Food and Drug Administration (FDA) use a permanent polymer-based drug release system. Balancing the need for lipophilicity (to bind active drug) with hydrophilicity (which offers superior biocompatibility) is a key challenge in polymer technology. Delayed arterial healing (DAH) following DES implantation has been demonstrated in human autopsy studies and animal models and is implicated in late thrombotic occlusion and delayed loss of antirestenotic efficacy. It is characterised by 1) persistent fibrin deposition; 2) delayed endothelialization; 3) chronic inflammation; and 4) persistent platelet activation. Within segment heterogeneity in degree of healing is typical. Inflammatory response to polymer residue plays an important role and may be non-specific (monocyte-macrophage predominant) or hypersensitivity related. Failure of early preclinical models to sufficiently predict DAH in man was an important problem. Second generation DES attempt to address the issue of DAH by using thinner stent struts, lower drug load and more biocompatible polymer. At present the focus of development is towards biodegradable polymer coatings which offer the attractive prospect of controlled drug-release without the potential for late polymer-associated adverse effects. This review highlights the role of polymer coatings in determination of DES efficacy, summarises the preclinical and clinical evidence linking polymer coatings with DAH and evaluates the promise of third generation polymer-free and biodegradable polymer DES.
Similar articles
-
Drug-eluting stents.Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Arch Cardiol Mex. 2006. PMID: 17091802 Review.
-
A review of current devices and a look at new technology: drug-eluting stents.Expert Rev Med Devices. 2009 Jan;6(1):33-42. doi: 10.1586/17434440.6.1.33. Expert Rev Med Devices. 2009. PMID: 19105778 Review.
-
Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing.J Interv Cardiol. 2009 Feb;22(1):37-48. doi: 10.1111/j.1540-8183.2009.00423.x. J Interv Cardiol. 2009. PMID: 19281521 Review.
-
Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.Indian Heart J. 2008 May-Jun;60(3):228-32. Indian Heart J. 2008. PMID: 19240312
-
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.Eur Heart J. 2009 Apr;30(8):923-31. doi: 10.1093/eurheartj/ehp044. Epub 2009 Feb 24. Eur Heart J. 2009. PMID: 19240066 Clinical Trial.
Cited by
-
Target and non-target vessel related events at 10 years post percutaneous coronary intervention.Clin Res Cardiol. 2022 Jul;111(7):787-794. doi: 10.1007/s00392-022-01986-4. Epub 2022 Feb 11. Clin Res Cardiol. 2022. PMID: 35147767 Free PMC article. Clinical Trial.
-
Stent implantation into the tracheo-bronchial system in rabbits: histopathologic sequelae in bare metal vs. drug-eluting stents.Mol Cell Pediatr. 2015 Dec;2(1):10. doi: 10.1186/s40348-015-0021-7. Epub 2015 Nov 5. Mol Cell Pediatr. 2015. PMID: 26542300 Free PMC article.
-
Preclinical Assessment of a Novel Polymer-Free Hybrid Drug Eluting Stent.J Cardiovasc Transl Res. 2025 Aug 15. doi: 10.1007/s12265-025-10680-5. Online ahead of print. J Cardiovasc Transl Res. 2025. PMID: 40815367
-
Drug diffusion and biological responses of arteries using a drug-eluting stent with nonuniform coating.Med Devices (Auckl). 2016 Mar 17;9:33-43. doi: 10.2147/MDER.S102094. eCollection 2016. Med Devices (Auckl). 2016. PMID: 27051322 Free PMC article.
-
In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease.J Interv Cardiol. 2023 Dec 13;2023:8907315. doi: 10.1155/2023/8907315. eCollection 2023. J Interv Cardiol. 2023. PMID: 38125031 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources